AstraZeneca announces two new phase IIIb trials for Forxiga in chronic kidney disease and chronic heart failure
First programme to assess potential cardiovascular and renal benefit of an SGLT-2i beyond diabetes
Ämnen: Farmaci
-
-
Benralizumab Phase III trials show positive results in severe asthma
AstraZeneca’s first biologic respiratory medicine met primary and key secondary endpoints in pivotal trials for severe asthma
-
AstraZeneca to present new data highlighting its growing respiratory portfolio and pipeline at European Respiratory Society 2016
New evidence to be presented includes pivotal Phase III data on benralizumab
-
AstraZeneca to sell small molecule antibiotics business to Pfizer
Value-creating divestment supports AstraZeneca’s focus on three main therapy areas Pfizer’s dedicated focus on infectious diseases will extend the reach of the antibiotics to more patients globally and maximise the potential of the late-stage, small molecule antibiotics business
-
AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease
Administration (FDA) Fast Track designation for the development programme in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in Phase III clinical trial. The FDA’s Fast Track programme is designed to expedite the development and review of new therapies to treat serious conditions and tackle key unmet medical needs.
-
AstraZeneca announces investment in Moderna
AstraZeneca today announced that it has increased its equity interest in Moderna Therapeutics (Moderna) with a $140 million investment as part of Moderna’s preferred-stock financing.
-
AstraZeneca provides update on phase III trial of selumetinib in non-small cell lung cancer
Selumetinib did not meet trial endpoint of progression-free survival in KRASm NSCLC patients.
-
AstraZeneca PLC:s resultatrapport för första halvåret och andra kvartalet 2016
De totala intäkterna minskade som förväntat med 3%, vilket återspeglar en minskning i produktförsäljning med 2% och är drivet av patentutgångar, i synnerhet Crestor i USA. Merparten av intäkterna från externa samarbeten förväntas ligga under andra halvåret.
-
AstraZeneca’s antibiotic Zavicefta met primary endpoints in phase III trial for treatment of hospital-acquired pneumonia
AstraZeneca today announced positive results from the Phase III REPROVE trial for Zavicefta (ceftazidime-avibactam), a new combination antibiotic for the treatment of a broad range of serious Gram-negative bacterial infections in hospitalised patients.
-
ASTRAZENECA RECEIVES APPROVAL IN THE EU FOR QTERN (SAXAGLIPTIN AND DAPAGLIFLOZIN) FOR TREATMENT OF TYPE 2 DIABETES
AstraZeneca today announced that the European Commission (EC) has approved Qtern (saxagliptin/dapagliflozin) tablets for the treatment of type 2 diabetes in all 28 EU member countries plus Iceland, Liechtenstein and Norway. The fixed-dose combination of saxagliptin and dapagliflozin is the first DPP-4i/SGLT-2i combination product to be approved in Europe.
-
Tagrisso met primary endpoint in Phase III 2nd-line lung cancer trial
Tagrisso demonstrated superior progression-free survival compared to standard platinum-based chemotherapy,with a safety profile consistent with previous trials First randomised trial to evaluate the clinical benefit of an EGFR T790M medicine, and data are consistent with those supporting Tagrisso approvals
-
Inbjudan till AstraZeneca och Läkartidningens seminarium i Almedalen om jämlik cancervård 4 juli 14.10-15.00
Hur får vi en jämlik cancerbehandling i Sverige och hur kan ”ordnat införande” bidra? Vilka utmaningar och möjligheter finns för introduktion av nya cancerbehandlingar idag? Hur har processen med nationellt ordnat införande förändrat vår förmåga att jämlikt kunna erbjuda nya behandlingar, över hela landet? Vilka är lärdomarna? Hur ser uppföljningen ut? Hur vill vi ha det om 5 år?
-
AstraZeneca enters licensing agreements with LEO Pharma in skin diseases
Agreement for development and commercialisation of tralokinumab for atopic dermatitis supports sharper focus on main therapy areas
AstraZeneca also licenses European rights to LEO Pharma for brodalumab, a potential new medicine for psoriasis
AstraZeneca today announced that it has entered into agreements that support its strategic focus on three main therapy areas; Respiratory, Inflammation -
New antibiotic ZAVICEFTA approved in the European Union for patients with serious bacterial infections
AstraZeneca today announced that the European Commission (EC) has granted marketing authorisation for Zavicefta (ceftazidime-avibactam, previously known as CAZ AVI), a new combination antibiotic for the treatment of patients with serious Gram-negative bacterial infections requiring hospitalisation.
-
AstraZeneca provides update on FluMist Quadrivalent vaccine in the US for the 2016-17 influenza season
AstraZeneca today confirmed that the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has provided its interim recommendation on the use of FluMist® Quadrivalent Live Attenuated Influenza Vaccine (FluMist Quadrivalent) in the US for the 2016-2017 influenza season.
-
Christer Betsholtz appointed new Head of Karolinska Institutet and AstraZeneca’s Integrated Cardio Metabolic Centre
Karolinska Institutet and AstraZeneca have today announced the appointment of Professor Christer Betsholtz as the new Director of their Integrated Cardio Metabolic Centre (ICMC) in Stockholm, Sweden.
Christer Betsholtz,PhD, is a leading scientific authority in the field of vascular biology with more than 300 publications. He is currently professor with tenure at Uppsala University and Karolinsk -
AstraZeneca ingår kommersialiseringsavtal med Aspen för produktportföljen inom anestetika
Avtalet utökar den kommersiella räckvidden för anestetika och stödjer bolagets tydliga fokus på innovativa, nya läkemedel inom tre huvudterapiområden
-
LYNPARZA (OLAPARIB): LATEST DATA SUGGEST POTENTIAL OVERALL SURVIVAL ADVANTAGE IN PATIENTS WITH PLATINUM SENSITIVE OVARIAN CANCER
AstraZeneca presented (at ASCO in the evening of June 5) results from a third interim analysis of Study 19 that suggest an improvement in overall survival (OS) for patients with ovarian cancer treated with olaparib maintenance therapy following platinum-based chemotherapy. This was a secondary endpoint of the trial.
-
TAGRISSO (OSIMERTINIB) SHOWS CLINICAL ACTIVITY IN PATIENTS WITH LEPTOMENINGEAL DISEASE FROM LUNG CANCER
Osimertinib data reported at ASCO 2016 demonstrated improved neurological function in patients with EGFRm NSCLC and leptomeningeal disease Latest results reinforce pre-clinical evidence that osimertinib crosses the blood-brain barrier
-
AstraZeneca licenses Zurampic to Grünenthal GmbH in Europe and Latin America
Agreement includes rights to the fixed-dose combination of lesinurad and allopurinol in gout
Visa mer
Loading...